British Patient Capital invests in best-in-class venture and venture growth capital fund managers with a strong UK focus, as well as directly in the most promising later-stage businesses.
As the UK’s largest domestic investor in UK venture and venture growth opportunities, we are increasing access to, and the availability of, long-term, patient finance. We do this via three schemes, each one addressing specific market issues.
Across all its activities, British Patient Capital invests on a commercial basis to deliver competitive returns for the UK taxpayer. By demonstrating that a patient capital approach can produce commercially attractive returns, we are encouraging other UK institutional investors to invest in the asset class, to both drive and benefit from the success of our high-growth companies.
Learn more about what British Patient Capital do
Core funds and co-investment programme
Through our core £2.5bn programme we invest in venture and venture growth capital funds, and co-invest alongside those funds in the most promising later-stage UK businesses within our portfolio.
Future Fund: Breakthrough
Future Fund: Breakthrough is a £425m UK-wide programme which encourages private investors to co-invest in growth stage, Research & Development (R&D) UK companies operating in breakthrough technology sectors.
Life Sciences Investment Programme
The Life Sciences Investment Programme (LSIP) is a £200m initiative which makes cornerstone commitments to later stage life sciences venture growth funds with a strong UK focus.